Share This Link

Administering the medication as prescribed could result in toxicity if the client’s drug levels are not within the therapeutic range.

Administering half the dose of the medication is not appropriate without consulting the provider and monitoring the client’s drug levels.

Administering the medication with food or milk may affect its absorption but does not prevent potential toxicity.

Oral administration would result in lower bioavailability due to first-pass metabolism.

Subcutaneous administration may also be subject to first-pass metabolism.

Intramuscular administration may also be subject to first-pass metabolism.

The client may require a higher, not lower, dose of the medication due to accumulation in adipose tissue.

More frequent dosing may not be necessary if an appropriate dose is administered.

The client’s body fat percentage can affect pharmacokinetics by altering distribution of lipophilic medications.

The medication will have decreased, not increased, absorption in an alkaline environment due to increased ionization.

The antacid can affect absorption by altering gastric pH and increasing ionization of weakly acidic medications.

The antacid can affect absorption but does not directly affect excretion of weakly acidic medications.

Giving the drug with food may affect its absorption but does not directly affect its activation by hepatic enzymes.

Giving the drug with an enzyme inducer, not an enzyme inhibitor, can increase its efficacy by increasing hepatic enzyme activity.

A prodrug is an inactive compound that requires conversion into its active form by metabolic processes such as hepatic enzyme activation.Giving a prodrug with an enzyme inducer can increase the activity of the hepatic enzymes responsible for converting the prodrug into its active form, potentially increasing its efficacy.

The client may require a lower, not higher, dose of the medication due to reduced renal excretion.

More frequent dosing may not be necessary if an appropriate dose is administered.

The client’s renal function can affect pharmacokinetics by altering excretion of medications that are primarily eliminated by the kidneys.

The client may have an increased, not decreased, free fraction of the drug due to reduced protein binding.

An increased volume of distribution may occur if protein binding is reduced, but this is not directly related to hypoalbuminemia.

The client’s albumin levels can affect pharmacokinetics by altering protein binding of highly protein-bound medications.

The drug will have a longer, not shorter, half-life due to repeated reabsorption and recirculation.

Enterohepatic recirculation can affect half-life but does not directly affect bioavailability.

Enterohepatic recirculation can affect half-life but does not directly affect bioavailability.

There is an increased, not decreased, risk of drug interactions due to accelerated metabolism of other medications.

There is an increased risk of drug interactions due to accelerated metabolism of other medications.

CYP450 induction can affect pharmacokinetics by altering metabolism of other medications that are substrates for these enzymes.

There is an increased, not decreased, risk of drug interactions due to increased concentration of other medications that are substrates for P-glycoprotein.

There is an increased risk of drug interactions due to increased concentration of other medications that are substrates for P-glycoprotein.

P-glycoprotein inhibition can affect pharmacokinetics by altering absorption, distribution, and elimination of other medications that are substrates for this protein.